Planning primary prevention of coronary disease

Current Atherosclerosis Reports

Volumn 11, Issue 4, 2009, Pages 272-280

  Lands, Bill ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; DOCOSAHEXAENOIC ACID; EZETIMIBE; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INDAPAMIDE PLUS PERINDOPRIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST CONTROL; DEPRESSION; DIABETES MELLITUS; DIET THERAPY; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TISSUE LEVEL; ENERGY EXPENDITURE; FAT INTAKE; FOOD INTAKE; HEALTH CARE COST; HEALTH INSURANCE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MOOD DISORDER; MORTALITY; PATIENT MONITORING; PREDICTION; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; UNITED STATES; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; CHOLESTEROL; DIET; ENERGY METABOLISM; FATTY ACIDS, UNSATURATED; HEALTH PLANNING; HUMANS; INFLAMMATION MEDIATORS; RISK FACTORS; UNITED STATES;

EID: 67649094344     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0042-6     Document Type: Review

References (51)

1. Centers for Disease Control and Prevention: About Heart Disease and Stroke Prevention at CDC. Available at http://www.cdc.gov/DHDSP/ about_program.htm. Accessed January 15, 2009.
2. AHA Statistics Committee and Stroke Statistics Subcommittee: Heart Disease and Stroke Statistics - 2009 Update. Circulation 2009 (in press).
3. De Gruttola VG, Clax P, DeMets DL, et al.: Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials: Summary of a National Institutes of Health Workshop. Control Clin Trials 2001, 22:485-502.
4. Lands WE: Primary prevention in cardiovaMcular disease: moving out of the shadows of the truth about death. Nutr Metab Cardiovasc Dis 2003, 13:154-164.
5. Lands B: A critique of paradoxes in current advice on dietary lipids. Prog Lipid Res 2008, 47:77-106.
6. Steinberg D: ThemaTic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy. Part IV: The 1984 coronary primary prevention trial ends it - almost. J Lipid Res 2006, 47:1-14.
7. Consensus conference: Lowering blood cholesterol to prevent heart disease. JAMA 1985, 253:2080-2086.
8. Wang CY, Liu PY, Liao JK: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008, 14:37-44.
9. Liu PY, Liu YW, Lin LJ, et al.: Evidence for statin pleiotropy in humans. differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2008 Dec 15 [Epub ahead of print].
10. Shi H, Kokoeva MV, Inouye K, et al.: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025.
11. Kim F, Pham M, Maloney E, et al.: Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 2008, 28:1982-1988.
12. Zieske AW, Malcom GT, Strong JP: Natural history and risk factors of atherosclerosis in children and youth: The PDAY study. Pediatr Pathol Mol Med 2002, 21:213-237.
13. Lands WE, Libelt B, Morris A, et al.: Maintenance of lower proportions of n-6 eicosanoid precursors in phospholipids of human plasma in response to added dietary n-3 fatty acids. Biochem Biophys Acta 1992, 1180:147-162.
14. Lands WE: Diets could prevent many diseases. Lipids 2003, 18:317-321.
15. Studer M, Briel M, Leimenstoll B, et al.: Effect of different antilipidemic agents and diets on mortality: A systematic review. Arch Intern Med 2005, 165:725-730.
16. Krumholz HM, Lee TH: Redefining quality - implications of recent clinical trials. N Engl J Med 2008, 358:2537-2539.
17. Birtwhistle R: What ever happened to the Mediterranean diet? QJM 2008, 101:741-742.
18. Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
19. Carey J: Do cholesterol drugs do any good? Available at http://www.businessweek.com/magazine/content/08_04/b4068052092994.htm. Accessed on January 12, 2009.
20. Couzin J: Cholesterol veers off script. Science 2008, 322:220-223.
21. Hoogwerf BJ; Action to Control Cardiovascular Risk in Diabetes Study Group: Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleve Clin J Med 2008, 75:729-737.
22. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
23. Carey J: Heart disease: Not about cholesterol? Available at http://www.businessweek.com/bwdaily/dnflash/content/apr2008/ db20080414_688906.htm. Accessed on January 12, 2009.
24. Tsitouras PD, Gucciardo F, Salbe AD, et al.: High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Horm Metab Res 2008, 40:199-205.
25. Gissi-HF Investigators: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
26. Gissi-HF Investigators: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
27. Lands WE: Dietary Tat and health: the evidence and the politics of prevention: Careful use of dietary fats can improve life and prevent disease. Ann N Y Acad Sci 2005, 1055:179-192.
28. Kirihara Y, Hamazaki K, Hamazaki T, et al.: The relationship between total blood cholesterol levels and all-cause mortality in Fukui City, and meta-analysis of this relationship in Japan [in Japanese]. Shishitsu-Eiyogaku (J Lipid Nutr) 2008, 17:67-78.
29. Verschuren WM, Jacobs DR, Bloemberg BP, et al.: Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five year follow-up of the seven countries study. JAMA 1995, 274:131-136.
30. Lands WE: Functional foods in primary prevention or nutraceuticals in secondary prevention? Curr Top Nutraceut Res 2003, 1:113-120.
31. Stark KD: The percentage of n-3 highly unsaturated fatty acids in total HUFA as a biomarker for omega-3 fatty acid status in tissues. Lipids 2008, 43:45-53.
32. Ohta A, Mayo MC, Kramer N, Lands WE: Rapid analysis of fatty acids in plasma lipids. Lipids 1990, 25:742-747.
33. Marangoni F, Colombo C, Galli C: A method for the direct evaluation of the fatty acid status in a drop of blood from a fingertip in humans: applicability to nutritional and epidemiological studies. Anal Biochem 2004, 326:267-272.
34. Armstrong JM, Metherel AH, Stark KD: Direct microwave transesterification of fingertip prick blood samples for fatty acid determinations. Lipids 2008, 43:187-196.
35. Masood MA, Salem N Jr: High throughput analysis of plasma fatty acid methyl esters employing robotic transesterification and fast gas chromatography. Lipids 2008, 43:171-180.
36. Lee TH, Mencia-Huerta JM, Shih C, et al.: Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest 1984, 74:1922-1933.
37. Wada M, DeLong CJ, Hong YH, et al.: Enzymes and receptors of prostaglandin pathways with arachidonic acidderived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 2007, 282:22254-22266.
38. Erkkilä AT, Lichtenstein AH, Mozaffarian D, Herrington DM: Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am J Clin Nutr 2004, 80:626-632.
39. Harris WS, Kris-Etherton PM, Harris KA: Intakes of longchain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep 2008, 10:503-509.
40. Virtanen JK, Siscovick DS, Longstreth WT Jr, et al.: Fish consumption and risk of subclinical brain abnormalities on MRI in older adults. Neurology 2008, 71:439-446.
41. Lichtenstein AH, Appel LJ, Brands M, et al.: Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006, 26:2186-2191.
42. Healy B: From Fish Oil to Medicine: No nutrient is more important for decreasing cardio-vascular death - and more lacking - than omega-3. Available at http://health.usnews.com/articles/health/heart/2008/08/07/ from-fish-oil-tomedicine_print.htm. Accessed on January 16, 2009.
43. Block RC, Harris WS, Reid KJ, et al.: EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 2008, 197:821-828.
44. Siscovick DS, Raghunathan TE, King I, et al.: Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995, 274:1363-1367.
45. Erkkilä AT, Matthan NR, Herrington DM, Lichtenstein AH: Higher plasma docosahexaenoic acid is associated with reduced progression of coronary atherosclerosis in women with CAD. J Lipid Res 2006, 47:2814-2819.
46. Harris WS, Reid KJ, Sands SA, Spertus JA: Blood omega-3 and trans fatty acids in middle-aged acute coronary syndrome patients. Am J Cardiol 2007, 99:154-158.
47. Aarsetøy H, Pönitz V, Nilsen OB, et al.: Low levels of cellular omega-3 increase the risk of ventricular fibrillation during the acute ischaemic phase of a myocardial infarction. Resuscitation 2008, 78:258-264.
48. Mohrhauer H, Holman RT: The effect of dose level of essential fatty acids upon fatty acid composition of the rat liver. J Lipid Res 1963, 4:151-159.
49. Liou YA, King DJ, Zibrik D, Innis SM: Decreasing linoleic acid with constant alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma phospholipids in healthy men. J Nutr 2007, 137:945-952.
50. Freeman MP, HibEeln JR, Wisner KL, et al.: Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006, 67:1954-1967.
51. Amin AA, Menon RA, Reid KJ, et al.: Acute coronary syndrome patients with depression have low blood cell membrane omega-3 fatty acid levels. Psychosom Med 2008, 70:856-862.